← Back to patent-cliff list
Buccal Dexmedetomidine (Reconnect Labs)
Tier C — Watch / tradeBuccal Dexmedetomidine (Reconnect Labs)
Reconnect Labs
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRA2
Indications (approved)：Post-traumatic stress disorder, Insomnia and sleep disorders
Regional status
US
-
EU
Phase II
2025-09-30
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Buccal Dexmedetomidine (Reconnect Labs)?
Approved indications include: Post-traumatic stress disorder, Insomnia and sleep disorders.
When does the Buccal Dexmedetomidine (Reconnect Labs) patent expire?
No public expiry year is available for Buccal Dexmedetomidine (Reconnect Labs) yet; this page updates once verified.
How do I get a quote for Buccal Dexmedetomidine (Reconnect Labs) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30